David G. Brohawn

Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia

Joshua L. Roffman, David G. Brohawn, Adam Z Nitenson et al. · Schizophrenia Bulletin · 2011 · 77 citations · Full text

Genetics, Genetic Epidemiology, Folate Level +16

RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord

David G. Brohawn, Laura C. O’Brien, James P. Bennett · PLoS ONE · 2016 · 75 citations · Full text

Neurogenomics, Genetics, Immunology +26

RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer’s Disease and Parkinson’s Disease Subjects, and Increased Expression of Genes From Disease-Activated Microglia

James P. Bennett, Paula M. Keeney, David G. Brohawn · Frontiers in Neuroscience · 2019 · 38 citations · Full text

A Hypomethylating Variant of MTHFR, 677C>T, Blunts the Neural Response to Errors in Patients with Schizophrenia and Healthy Individuals

Joshua L. Roffman, Adam Z Nitenson, Yigal Agam et al. · PLoS ONE · 2011 · 28 citations · Full text

Pharmacological properties of microneurotrophin drugs developed for treatment of amyotrophic lateral sclerosis

James P. Bennett, Laura C. O’Brien, David G. Brohawn · Biochemical Pharmacology · 2016 · 23 citations

Amyotrophic Lateral Sclerosis, Microneurotrophin Drugs, Medicine +9